Aurora Cannabis Inc., a leading global medical cannabis company based in Canada, has announced its upcoming conference call to discuss the financial results for its second quarter of 2025. This event is part of the company’s commitment to keeping investors informed about its performance and strategic direction.
Conference Call Details
The conference call is set for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). Aurora will release its financial results for the second quarter before the markets open on the same day.
- Hosts: The call will be led by Miguel Martin, Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer.
- Webcast Access: Investors can access the conference call through a dedicated webcast link available on the company’s investor relations page.
This call provides an opportunity for stakeholders to gain insights into Aurora’s financial health and future plans, as well as to engage in a question-and-answer session.
About Aurora Cannabis
Aurora Cannabis is dedicated to serving both medical and consumer markets across Canada, Europe, Australia, and South America. The company is headquartered in Edmonton, Alberta, and is recognized as a pioneer in the global cannabis industry.
- Product Portfolio: Aurora’s adult-use brands include Drift, San Rafael ’71, Daily Special, Tasty’s, Being, and Greybeard. Its medical cannabis brands encompass MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co., among others.
- Innovation Focus: The company emphasizes high-quality cannabis products and is driven by science and innovation, aiming to improve the lives of its customers.
Aurora’s common shares are traded on both the NASDAQ and TSX under the symbol “ACB.”
Forward-Looking Statements
The announcement includes forward-looking statements regarding the timing of the financial results release and the conference call. These statements are based on management’s assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially.
Investors are encouraged to review the company’s annual information form for a comprehensive understanding of the risks associated with their investment in Aurora Cannabis
